{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:03:00Z","timestamp":1790251380941,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08897-2","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:25:05Z","timestamp":1788315905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal spatial multi-omics delineates tumor microenvironment remodeling across sequential EGFR-TKIs in EGFR-mutant NSCLC"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-8663","authenticated-orcid":false,"given":"Xinyu","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhikai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"10","key":"8897_CR1","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu Y-L, S S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0810699.","journal-title":"N Engl J Med"},{"issue":"2","key":"8897_CR2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR -Mutated advanced non\u2013small-Cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"1","key":"8897_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, D D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"4","key":"8897_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jtho.2023.01.006","volume":"18","author":"X Le","year":"2023","unstructured":"Le X. Resistance to EGFR inhibitors: fitness, competition, and diversity. J Thorac Oncol. 2023;18(4):390\u201392. https:\/\/doi.org\/10.1016\/j.jtho.2023.01.006.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"8897_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CCO.0000000000000805","volume":"34","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Yu D, Tian W, Wu F. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Curr Opin Oncol. 2022;34(1):54\u201365. https:\/\/doi.org\/10.1097\/CCO.0000000000000805.","journal-title":"Curr Opin Oncol"},{"issue":"8","key":"8897_CR6","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","volume":"19","author":"HA Yu","year":"2013","unstructured":"Yu HA, Arcila ME, N N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR -mutant lung cancers. Clin Cancer Res. 2013;19(8):2240\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2246.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"8897_CR7","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1158\/1078-0432.CCR-10-2277","volume":"17","author":"ME Arcila","year":"2011","unstructured":"Arcila ME, R GR, Nafa K, Riely GJ, Solomon SB, Zakowski MF, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2277.","journal-title":"Clin Cancer Res"},{"key":"8897_CR8","doi-asserted-by":"publisher","unstructured":"Passaro A, Malapelle U, Del REM, Attili I, Russo A, Guerini-Rocco E, et al. Understanding EGFR heterogeneity in lung cancer. ESMO Open. 2020;5(5):e000919. https:\/\/doi.org\/10.1136\/esmoopen-2020-000919.","DOI":"10.1136\/esmoopen-2020-000919"},{"key":"8897_CR9","doi-asserted-by":"publisher","unstructured":"Sequist LV, A BA, D D-S, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26. https:\/\/doi.org\/10.1126\/scitranslmed.3002003.","DOI":"10.1126\/scitranslmed.3002003"},{"issue":"1","key":"8897_CR10","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.xcrm.2020.100007","volume":"1","author":"N Roper","year":"2020","unstructured":"Roper N, Brown A-L, Wei JS, Pack S, Trindade C, Kim C, et al. Clonal evolution and heterogeneity of Osimertinib acquired resistance mechanisms in EGFR mutant lung cancer. Cell Rep Med. 2020;1(1):100007. https:\/\/doi.org\/10.1016\/j.xcrm.2020.100007.","journal-title":"Cell Rep Med"},{"key":"8897_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2021.06.022","volume":"159","author":"HS Rad","year":"2021","unstructured":"Rad HS, Rad HS, Shiravand Y, Radfar P, Arpon D, Warkiani ME, et al. The Pandora\u2019s box of novel technologies that may revolutionize lung cancer. Lung Cancer. 2021;159:34\u201341. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.022.","journal-title":"Lung Cancer"},{"issue":"2","key":"8897_CR12","doi-asserted-by":"publisher","first-page":"111736","DOI":"10.1016\/j.isci.2024.111736","volume":"28","author":"S Kim","year":"2025","unstructured":"Kim S, Koh J, M TM, Oh S, Kim S, Youk J, et al. Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer. iScience. 2025;28(2):111736. https:\/\/doi.org\/10.1016\/j.isci.2024.111736.","journal-title":"iScience"},{"issue":"5","key":"8897_CR13","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","volume":"38","author":"CR R","year":"2020","unstructured":"R CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586\u201399. https:\/\/doi.org\/10.1038\/s41587-020-0472-9.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"8897_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13402-025-01143-9","volume":"49","author":"C Yu","year":"2025","unstructured":"Yu C, Shi C, Zhou H, Li N, Ma R, Liu S, et al. Spatially resolved whole-transcriptomic profiling of EGFR-mutated lung adenocarcinomas stratified by PD-L1 expression. Cell Oncol. 2025;49(1):2. https:\/\/doi.org\/10.1007\/s13402-025-01143-9.","journal-title":"Cell Oncol"},{"issue":"1","key":"8897_CR15","doi-asserted-by":"publisher","first-page":"15534","DOI":"10.1038\/s41598-020-72664-6","volume":"10","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Wong L, Goh WWB. How to do quantile normalization correctly for gene expression data analyses. Sci Rep. 2020;10(1):15534. https:\/\/doi.org\/10.1038\/s41598-020-72664-6.","journal-title":"Sci Rep"},{"issue":"1","key":"8897_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14(1):7. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","journal-title":"BMC Bioinf"},{"issue":"1","key":"8897_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340. https:\/\/doi.org\/10.1093\/bioinformatics\/btp616.","journal-title":"Bioinformatics"},{"key":"8897_CR18","doi-asserted-by":"publisher","unstructured":"Bu D, Luo H, Huo P, Wang Z, Zhang S, He Z, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 2021;49(W1):W317\u201325. https:\/\/doi.org\/10.1093\/nar\/gkab447.","DOI":"10.1093\/nar\/gkab447"},{"issue":"18","key":"8897_CR19","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u201349. https:\/\/doi.org\/10.1093\/bioinformatics\/btw313.","journal-title":"Bioinformatics"},{"issue":"8","key":"8897_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19(8):499\u2013514. https:\/\/doi.org\/10.1038\/s41571-022-00639-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8897_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","volume":"14","author":"J Chmielecki","year":"2023","unstructured":"Chmielecki J, Mok T, Wu Y-L, Han J-Y, Ahn M-J, Ramalingam SS, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14(1):1071. https:\/\/doi.org\/10.1038\/s41467-023-35962-x.","journal-title":"Nat Commun"},{"issue":"1","key":"8897_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41467-024-55378-5","volume":"16","author":"B Alsaed","year":"2025","unstructured":"Alsaed B, Lin L, Son J, Li J, Smolander J, Lopez T, et al. Intratumor heterogeneity of EGFR expression mediates targeted therapy resistance and formation of drug tolerant microenvironment. Nat Commun. 2025;16(1):28. https:\/\/doi.org\/10.1038\/s41467-024-55378-5.","journal-title":"Nat Commun"},{"issue":"7948","key":"8897_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41586-022-05672-3","volume":"614","author":"M Sorin","year":"2023","unstructured":"Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, et al. Single-cell spatial landscapes of the lung tumour immune microenvironment. Nature. 2023;614(7948):548\u201354. https:\/\/doi.org\/10.1038\/s41586-022-05672-3.","journal-title":"Nature"},{"issue":"5","key":"8897_CR24","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41592-022-01409-2","volume":"19","author":"L Moses","year":"2022","unstructured":"Moses L, Pachter L. Museum of spatial transcriptomics. Nat Methods. 2022;19(5):534\u201346. https:\/\/doi.org\/10.1038\/s41592-022-01409-2.","journal-title":"Nat Methods"},{"issue":"1","key":"8897_CR25","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/ijms27010445","volume":"27","author":"LYE Lau","year":"2025","unstructured":"Lau LYE, Skanderup AJ, Tan AC. Lineage plasticity and histologic transformation in EGFR-TKI resistant lung cancer. IJMS. 2025;27(1):445. https:\/\/doi.org\/10.3390\/ijms27010445.","journal-title":"IJMS"},{"issue":"8","key":"8897_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41419-024-06940-y","volume":"15","author":"M Izumi","year":"2024","unstructured":"Izumi M, Fujii M, S IS, Ho V, Kashima Y, Udagawa H, et al. Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer. Cell Death Dis. 2024;15(8):580. https:\/\/doi.org\/10.1038\/s41419-024-06940-y.","journal-title":"Cell Death Dis"},{"issue":"11","key":"8897_CR27","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/2159-8290.CD-21-1714","volume":"12","author":"JA Grout","year":"2022","unstructured":"Grout JA, Sirven P, Leader AM, Maskey S, Hector E, Puisieux I, et al. Spatial positioning and matrix programs of cancer-associated fibroblasts promote T-cell exclusion in human lung tumors. Cancer Discov. 2022;12(11):2606\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1714.","journal-title":"Cancer DiscovCancer Discov"},{"key":"8897_CR28","doi-asserted-by":"publisher","unstructured":"Chen C, Guo Q, Liu Y, Hou Q, Liao M, Guo Y, et al. Single-cell and spatial transcriptomics reveal POSTN + cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer. Clin Transl Med. 2023;13(12):e 1515. https:\/\/doi.org\/10.1002\/ctm2.1515.","DOI":"10.1002\/ctm2.1515"},{"issue":"8","key":"8897_CR29","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1158\/1078-0432.CCR-19-2027","volume":"26","author":"K Isomoto","year":"2020","unstructured":"Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation\u2013positive non\u2013small cell lung cancer. Clin Cancer Res. 2020;26(8):2037\u201346. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2027.","journal-title":"Clin Cancer Res"},{"issue":"64","key":"8897_CR30","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.18632\/oncotarget.22582","volume":"8","author":"T-J Kim","year":"2017","unstructured":"Kim T-J, Hong SA, Kim O, Kim SJ, Yang J-H, Joung EK, et al. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget. 2017;8(64):107630\u201339. https:\/\/doi.org\/10.18632\/oncotarget.22582.","journal-title":"Oncotarget"},{"issue":"18","key":"8897_CR31","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","volume":"22","author":"JF Gainor","year":"2016","unstructured":"Gainor JF, Shaw AT, Sequist LV, Fu X, Azzoli CG, Piotrowska Z, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non\u2013small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585\u201393. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-3101.","journal-title":"Clin Cancer Res"},{"key":"8897_CR32","doi-asserted-by":"publisher","unstructured":"Song X, Xiong A, Wu F, Li X, Wang J, Jiang T, et al. Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody. J Immunother Cancer. 2023;11(2):e006234. https:\/\/doi.org\/10.1136\/jitc-2022-006234.","DOI":"10.1136\/jitc-2022-006234"},{"issue":"2","key":"8897_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","volume":"12","author":"CK Lee","year":"2017","unstructured":"Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, et al. Checkpoint inhibitors in metastatic EGFR- mutated non\u2013small cell lung cancer\u2014A meta-analysis. J Thorac Oncol. 2017;12(2):403\u201307. https:\/\/doi.org\/10.1016\/j.jtho.2016.10.007.","journal-title":"J Thorac Oncol"},{"issue":"7","key":"8897_CR34","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdx183","volume":"28","author":"K Haratani","year":"2017","unstructured":"Haratani, K, and Hayashi, H Tanaka, T et al. 2017 Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28 7 1532\u20139.","journal-title":"Ann Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08897-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08897-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:11:14Z","timestamp":1790248274000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08897-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8897"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08897-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8920893\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Shanghai Pulmonary Hospital (Approval No.L24-404\u20131). The study was conducted inaccordance with the Declaration of Helsinki (as revised in 2013). Informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1212"}}